SGS withdraws GI Dynamics' CE Mark & more — 6 GI company key notes

Written by Eric Oliver | November 22, 2017 | Print  |

Here are six updates on GI companies from the past week:

SGS United Kingdom withdrew GI Dynamics' CE Mark for its EndoBarrier device.

IQuility is releasing IsolateIBS-IBD, a RNA-based blood test that can help physicians identify irritable bowel syndrome or inflammatory bowel disease.

After discontinuing a drug therapy program that "did not live up to its promise," Outpost Medicine shifted its focus towards OP-687, an oral therapy for overactive bladder and irritable bowel syndrome.

After announcing positive results from its second phase III trial, Global Data Healthcare Analysts' Maria Sudul said Ardelyx's Tenapanor is in line to make a "successful market entry."

Lumendi completed the first in-human trials of its DiLumen Endolumenal Interventional Platform technology, meeting the study's primary endpoint.

The U.S. Patent and Trademarks Office granted Immuron a patent for its non-alcoholic steatohepatitis treatment.

More articles on gastroenterology: 
GI leader to know: Dr. Donald Gerhardt of Gastrointestinal Associates
Stock market week-in-review for 5 large GI companies — Nov. 13-17
Outpost Medicine pivots to 'new class of oral therapy' for IBS — 3 insights

© Copyright ASC COMMUNICATIONS 2018. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

To receive the latest hospital and health system business and legal news and analysis from Becker's Hospital Review, sign-up for the free Becker's Hospital Review E-weekly by clicking here.